nvm i re-read their analysis and risk and it state:
We see Immunotherapies as the key variable in our valuation over the next 12 months. Should COR-1 (Phase II) and COR-2 (Phase Ib) both achieve positive clinical results in their current trials, and assuming no significant change in the viral shedding rate released with the COR-1 interim results, our valuation rises to 58c/share. With respect to downside risk, should both clinical programs fail, we would ascribe a zero value to Immunotherapies (at least until such time as the two HPV pre-clinical programs enter the clinic), and our valuation would fall to 39c/share.
however, the result is not negative either, so idk should i be bothered to invest here atm or not LOL
Ann: Response to Aware Query, page-14
-
- There are more pages in this discussion • 68 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.49 |
Change
0.490(4.08%) |
Mkt cap ! $264.0M | |||
| Open | High | Low | Value | Volume |
| $12.11 | $12.49 | $11.50 | $155.8K | 13.16K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 175 | $11.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.49 | 77 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |